12:00 AM
Apr 26, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dexpramipexole: Additional Phase II data

A post hoc analysis of a double-blind, placebo-controlled, U.S. Phase II trial showed that 50, 150 and 300 mg/day KNS-760704 for 12 weeks displayed a significant dose-dependent trend in reducing treatment failure as measured by both the ALS Functional Rating Scale-Revised (ALSFRS-R) and forced vital capacity. Specifically, treatment failure defined as a >=6 point loss in ALSFRS-R scores from baseline was 35%, 15% and...

Read the full 298 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >